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Introduction
Antimicrobial peptides are effector molecules of the
innate immune system with microbicidal and proin-
flammatory activities (1, 2). Cathelicidins are one fam-
ily of antimicrobial peptides characterized by con-
served propeptide sequences that were identified in
several mammalian species. LL-37/hCAP-18 is the only
antimicrobial peptide of the cathelicidin family iden-
tified from humans (3). It is expressed in leukocytes
such as neutrophils, monocytes, NK cells, γδ T cells,
and B cells (4–8), and in epithelial cells of the testis,
skin (8, 9), the gastrointestinal tract, and the respira-
tory tract (4). The 37-amino acid–long C terminus rep-
resents the antimicrobially active peptide and is
referred to as LL-37. LL-37 has been identified in plas-
ma (10), in the airway surface fluid (4, 11), and in
wound secretions (9). The peptide is induced by
inflammatory or infectious stimuli and displays direct
antimicrobial activity by interaction with the cell
membranes of microorganisms (2). Mice with dis-
rupted Cnlp, the gene coding for CRAMP (cathelin-
related antimicrobial peptide), showed increased sus-
ceptibility to skin infections with group A Streptococcus
(12). CRAMP shows several close similarities to human
LL-37, including an α-helical conformation, compa-
rable spectra of antimicrobial activity, and analogous
tissue distribution. A deficiency of LL-37/hCAP-18 in
the skin of patients with atopic dermatitis may account
for the increased susceptibility to skin infections (13).
Recently, LL-37 was found to bind to formyl peptide
receptor-like 1 (FPRL1), a G protein–coupled, seven-
transmembrane cell receptor found on macrophages,
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for cutaneous wound neovascularization in vivo. Taken together, these findings demonstrate that
LL-37/hCAP-18 is a multifunctional antimicrobial peptide with a central role in innate immunity by
linking host defense and inflammation with angiogenesis and arteriogenesis.
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neutrophils, and subsets of lymphocytes (14). Catheli-
cidin antimicrobial peptides seem to play a central role
in host defense by direct antimicrobial activity and
modulation of inflammation. The role of antimicro-
bial peptides as effector molecules of innate immuni-
ty is widening from solely endogenous antibiotics to
multifunctional mediators that provide a first line of
host defense, modify the local inflammatory response,
and activate adaptive immunity.
The formation of new blood vessels is a prerequisite
of tissue repair and wound healing (15, 16). Vascular-
ization is initiated by various factors ranging from
mechanical stress and hypoxia to the presence of solu-
ble inflammatory mediators (16) and involves the
sprouting of small capillaries (angiogenesis) and the
growth of preexisting vessels (arteriogenesis). Here we
demonstrate that LL-37 induces functionally impor-
tant angiogenesis and arteriogenesis. Furthermore, we
provide evidence that the angiogenic activity of LL-37
is mediated by a direct action on endothelial cells.
Methods
Cell proliferation assays and Matrigel assays. Human umbil-
ical vein endothelial cells (HUVECs; 104) (17) seeded on
six-well plastic dishes were stimulated with the follow-
ing substances in different concentrations: LL-37 (37 
C-terminal amino acids), WKYMVm (W peptide) (500
ng/ml; Humboldt University, Berlin, Germany),
VEGF165 (5 ng/ml; Sigma-Aldrich Chemie GmbH,
Munich, Germany), a scrambled version of LL-37 called
sLL-37 (RSLEGTDRFPFVRLKNSRKLEFKDIKGIKRE-
QFVKIL), hBD-3 synthesized as described earlier (18),
human α-defensins isolated from neutrophil granules
as a mixture of human neutrophil peptide–1 (HNP-1), 
-2, and -3, as described previously (19), and the recom-
binant hCAP-18 (20). After 72 hours, the cells were
detached and counted. For inhibition experiments we
applied human serum (10%), pertussis toxin (10 ng/ml,
Sigma-Aldrich Chemie GmbH), an antiserum against
FPRL1 (21) or VEGF (Sigma-Aldrich Chemie GmbH),
or inhibitors of MAPK extracellular signal-regulated
kinase (PD98059; 10 µM), p38 MAPK (SB203580; 10
µM), phospholipase C (PLC) (U-7312; 10 µM), PI3K
(wortmannin; 100 nM), and PKC (GF109203X; 0.3 µM).
HUVECs were cultivated on Matrigel support (Becton
Dickinson and Co., Franklin Lakes, New Jersey, USA) in
serum-free medium. After 18 hours, the cultures were
inspected for the formation of rings and cords. VEGF
levels in the medium were determined by ELISA.
Hamster aortic ring sprouting. Aortae from golden Syri-
an hamsters were cross-sectioned into rings and
mounted onto plastic dishes. Matrigel (150 µl; BD Bio-
sciences, Bedford, Massachusetts, USA) was placed on
top and allowed to gel. After 6 days, the aortic rings
were fixed with 3.7% formaldehyde and analyzed under
an inverted microscope.
Measurement of intracellular calcium. HUVECs grown on
glass slides were loaded with 2 µM Fura-2 AM (Molec-
ular Probes Inc., Eugene, Oregon, USA). After the wash-
es, the cells were observed on a fluorescence microscope
(Axiovert 100; Carl Zeiss GmbH, Oberkochen, Ger-
many) by alternative illumination at 340 nm and 380
nm by a monochromator (Till Photonics GmbH,
Munich, Germany). The ratios of the fluorescence
intensities were calculated representing the relative
intracellular calcium concentration. The test sub-
stances were locally applied into the buffer.
NF-κB translocation assay. HUVECs were stimulated
with peptides or TNF-α as positive control for 4
hours. Activation of NF-κB was determined by the
distribution of its subunit p65 between the cytoplasm
and nucleus in immunofluorescence images as
described previously (17).
Apoptosis of endothelial cells. Apoptosis of HUVECs was
measured by quantifying annexin V binding by flow
cytometry. HUVECs were incubated with the respective
peptide (5 µg/ml) for 5 hours and then carefully
detached from the culture dish using citrate buffer.
The following staining procedure was performed
according to the manufacturer’s handbook (Apoptosis
Detection Kit I; PharMingen, Heidelberg, Germany).
Wound model in Cnlp-deficient mice. Age- and sex-
matched 129/SVJ mice with disrupted genes for Cnlp
(12) and wild-type mice were sacrificed 3 days after a
1-cm-long linear skin incision was made, as previous-
ly described (22). Frozen sections were immunolabeled
using rat mAb’s against murine platelet endothelial
cell adhesion molecule-1 (PECAM-1) (clone MEC 13.3;
PharMingen, San Diego, California, USA). Blood ves-
sels were counted using a secondary biotinylated goat
anti-rat IgG (Vectastain ABC Elite; Vector Laborato-
ries, Burlingame, California, USA).
Chorioallantoic membrane assay. Chorioallantoic mem-
brane (CAM) assays were performed in hen eggs as
described previously (23). Dried aliquots of a mixture
of 5 µl solvent (water), with or without peptide, with 5
µl of 1% methylcellulose were placed onto the CAMs
and incubated for 3 days. After injection of 20%
Luconyl black 0600 (BASF, Ludwigshafen, Germany),
photographs were taken. CAMs were fixed, embedded
in paraffin, sectioned, stained with a Masson-Goldner
solution, and vessels were counted in hot spots as
described previously (24).
Rabbit model of angiogenesis. German/Giant rabbits
(6.5 ± 0.4 kg) were subjected to excision of the proxi-
mal external iliac, the popliteal, and the distal saphe-
nous arteries (25). After 7 days, 200 µg LL-37, 200 µg
sLL-37, 50 µg bFGF/20 µg VEGF, or PBS alone were
injected in five portions into the muscles of the medi-
al thigh and the calf (five injection sites; n = 4/group).
Seven and 35 days after surgery, angiography was per-
formed by injection of contrast agent into the abdom-
inal aorta (4 ml at 2 ml/s; cineangiography 25 frames/s)
(Siemens, Munich, Germany). Collateral growth was
defined as the increase in angiographic collateral score
between 7 and 35 days after initial surgery (assessed by
counting the contrast-opacified collateral vessels in
the medial thigh using a grid overlay) (26). Blood flow
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was assessed by cinedensitometry of the passage time of
the contrast agent between the common iliac artery and
the anterior tibial artery (27). Tissue specimens were sam-
pled from the gastrocnemius and fibularis muscles, cap-
illaries were detected by alkaline phosphatase staining
with indoxyl-tetrazolium, and capillary density was
assessed as ratio of capillaries to muscle fibers. Tissue sec-
tions were immunostained for the presence of cells posi-
tive for CD5, CD11b, CD68, or myeloperoxidase (Serotec
GmbH, Dusseldorf, Germany). Numbers of positive cells
were counted in ten microscopic fields per section.
Expression of FPRL1. RT-PCR was performed using
total RNA from HUVECs, macrophages, and BEAS-2B
cells, using Trizol reagent and the Superscript II reverse
transcriptase system (both from Life Technologies Inc.,
Karlsruhe, Germany) and the following primers based
on the GenBank file (NM001462): sense, 5′-GAC CTT
GGA TTC TTG CTC TAG TC-3′ and antisense, 5′-CCA TCC
TCA CAA TGC CTG TAA C-3′, as described earlier (28). For
immunohistochemistry, formalin-fixed and paraffin-
embedded human lung tissue was sectioned and incu-
bated with rabbit antiserum to FPRL1 or control serum.
Bound Ab’s were visualized using a peroxidase-labeled
secondary Ab and AEC Single Solution (Zymed, Berlin,
Germany). Western blots were prepared for analysis as
described previously using 10% PAGE gels (4).
Statistical analysis. Values are displayed as mean plus or
minus SEM. Comparisons between groups were ana-
lyzed by the t test (two-sided) or ANOVA for experi-
ments with more than two subgroups. Post hoc range
tests were performed with the t test (two-sided) with a
Bonferroni adjustment. Results were considered statis-
tically significant for P values less than 0.05.
Results
LL-37 stimulates physiologic and pathologic angiogenesis in
vivo. To test the hypothesis that LL-37 may play a role
in induction of angiogenesis, we analyzed activities of
LL-37 in different in vivo models for angiogenesis and
arteriogenesis. When the peptide was applied in the
CAM assay, a model for physiologic angiogenesis, a sig-
nificant induction of vessel growth was observed at
doses of 5 µg/pellet (Figure 1, a–c). LL-37 induced ves-
sel growth inside CAM areas beneath the pellet, which
revealed a typical wheel spoke–like structure similar to
the positive control bFGF (Figure 1a) (29). A quantita-
tive analysis revealed a large increase of erythrocyte-
filled blood vessels and connective tissue in LL-37–treat-
ed samples (Figure 1b). A scrambled version of LL-37,
called sLL-37, resulted in no increase of blood vessels in
comparison with the solvent control (Figure 1, a–c).
In addition, we applied LL-37 in a rabbit hind-limb
model to assess the effect of the peptide on both angio-
genesis and the induction of collateral circulation
under pathologic conditions. In this model angiogen-
esis and collateral vessel growth (arteriogenesis) are
induced by excision of the femoral artery. Seven days
after surgical excision of the femoral artery, baseline
measurements were performed, and LL-37, control
peptides, or buffer were injected into the ischemic hind
limb. Four weeks after injection we found significant-
ly increased collateral vessel growth in the ischemic
hind limbs of the LL-37 group as compared with ani-
mals injected with sLL-37 or buffer alone (Figure 2,
a–e). Quantitative histologic evaluation of the muscles
of the limb revealed higher capillary density in the calf
muscles of the animals treated with the antimicrobial
peptide, indicating that not only arteriogenesis but also
angiogenesis is induced in this model (Figure 2f). Final-
ly, we found increased blood flow velocity between the
internal iliac artery and the anterior tibial artery in the
LL-37–exposed animals as compared with the negative
control groups (Figure 2g). Immunohistologic analysis
The Journal of Clinical Investigation | June 2003 | Volume 111 | Number 11 1667
Figure 1
LL-37 induces physiologic angiogenesis in the CAM assay. (a) LL-37
(5 µg/pellet) induces the formation of wheel spoke–like vessel for-
mation in comparison with the scrambled control peptide sLL-37 or
the solvent. bFGF was used as positive control. Bars: 1 mm. (b)
Cross sections of CAMs. LL-37 increases the number of erythro-
cyte-filled vessels (Masson-Goldner stain of erythrocyte-filled ves-
sels). Bars: 250 µm or 62 µm in the ×10 and ×40 micrographs,
respectively. (c) The numbers of erythrocyte-filled vessels were
counted in hot spots. *P < 0.05 as compared with the solvent
group (n = 6/group; three sections per CAM). 
of inflammatory cells 3 days or 4 weeks after injection
revealed no significant increase of CD5, CD11b, CD68,
or myeloperoxidase-positive cells (data not shown).
These data show that LL-37/hCAP-18 induces angio-
genesis in vivo in both models of physiologic and
pathologic angiogenesis and that this is accompanied
by functionally relevant increased blood supply.
Murine CRAMP is necessary for normal wound vascular-
ization. The cathelicidin antimicrobial peptide CRAMP
is the putative murine homologue of LL-37/hCAP-18.
To test whether mice with disrupted Cnlp genes coding
for CRAMP have impaired vascularization of wounds,
we injured animals by full-thickness aseptic linear inci-
sions. As described previously, this method of injury
results in a large increase in cathelicidins at the wound
edge in both normal mice and humans (22). Neovascu-
larization at the wound edge was observed histological-
ly 3 days after injury. CD31 (PECAM-1) expression on
endothelial cells was evaluated by immunohistochem-
istry to clearly identify vascular structures. We found
that CRAMP-deficient mice had significantly decreased
vascular structures at the wound edge when compared
with normal animals matched for age and sex (Figure 3,
a–c). No apparent difference was seen in the total num-
ber of vessels observed in the normal dermis distant
from the site of injury. These results provide strong evi-
dence that cathelicidins are necessary for wound vascu-
larization in vivo.
LL-37 induces angiogenesis by a direct effect on endothelial
cells. To address the question whether the angiogenic
activities of LL-37 can be explained by a direct action on
endothelial cells we applied LL-37 in several in vitro and
ex vivo models of angiogenesis. We measured the effect
of LL-37 on proliferation of HUVECs and found that
addition of the peptide resulted in a dose-dependent
increase of cell proliferation with a minimal effective
concentration as low as 50 ng/ml (Figure 4a). The pro-
liferative function of LL-37 could not be blocked by the
presence of 10% human serum (Figure 4a), which was
demonstrated previously to abrogate the antimicrobial
activity of LL-37 (30). At equimolar concentrations,
other peptides, including HNPs, hBD-3, and the propep-
tide hCAP-18, had no effect on endothelial proliferation
1668 The Journal of Clinical Investigation | June 2003 | Volume 111 | Number 11
Figure 2
LL-37 induces angiogenesis and arteriogenesis in the rabbit hind-limb
model. (a–d) Application of the peptide in a rabbit hind-limb model
resulted in increased collateral growth in the LL-37–treated animals
(a) as compared with the sLL-37–treated animals (b) or the buffer
control group (c). bFGF/VEGF was used as positive control (d). (e)
Collateral growth was significantly increased in the LL-37 group. (f)
Tissue specimens from the calf (gastrocnemius muscle) revealed high-
er capillary density in the treated group as compared with the control
group. (g) Blood flow velocity as assessed by cinedensitometry of the
passage time of the contrast agent between the internal iliac artery
and the anterior tibial artery was significantly augmented in the LL-37
group. *P < 0.05 as compared with the buffer control (n = 4/group).
Figure 3
Mice with disrupted Cnlp gene show decreased wound revasculariza-
tion. (a and b) Vascular structures are identified in microsections by
CD31 immunostaining at the wound edge 3 days after full-thickness
aseptic injury. An asterisk denotes the wound site and location of
crust. Wild-type 129/SvJ mice show multiple vascular structures in
granulation tissue at the margin of the repairing wound (a). Mice
with homozygous deletion of Cnlp, therefore lacking CRAMP, have
fewer vessels at an identical location relative to the wound (b). The
bar = 12.5 µm in both micrographs. (c) Numbers of vessels in the
skin near the site of injury are significantly decreased in Cnlp–/– com-
pared with wild-type mice, but are similar distal to the wound in each
group (*P < 0.05; n = 3/group, three sections per animal).
(Figure 4a). To investigate whether LL-37 might influ-
ence angiogenesis by induction of VEGF synthesis, we
determined VEGF levels in the cell culture supernatants
by ELISA and found no increased concentrations after
stimulation with LL-37 (data not shown). Furthermore,
coincubation with neutralizing anti-VEGF Ab’s did not
reduce the LL-37–induced proliferation of endothelial
cells (data not shown). Next, we measured the formation
of vascular structures by applying LL-37 in an in vitro
Matrigel assay and observed the formation of visible
rings and cords of endothelial cells in response to LL-37
but not to the control substances, including other
antimicrobial peptides (data not shown). In addition,
LL-37 stimulated outgrowth of endothelial cells from
hamster aortic rings in an ex vivo sprouting assay simi-
lar to bFGF (Figure 4, b and c). HNPs or hCAP-18 had no
effect on the sprouting of endothelial cells (Figure 4c).
These data demonstrate that LL-37/hCAP-18 directly
activates endothelial cells and induces endothelial
sprout formations both in vitro and ex vivo.
Angiogenic activities of LL-37 in endothelial cells are medi-
ated by FPRL1 signaling. We next analyzed the mecha-
nisms involved in the angiogenic activity of LL-37.
Because the peptide LL-37 was shown to bind to FPRL1
(14), we tested whether HUVECs express FPRL1.
Indeed, we observed expression of FPRL1 in HUVECs
as a 620-bp product of a RT-PCR (Figure 5a) and a pos-
itive signal in a Western blot using antiserum against
FRPL1 (Figure 5b). DNA sequence analysis of the PCR
product confirmed 100% identity with the correspon-
ding cDNA sequence of FPRL1 (data not shown). In the
next step we analyzed the tissue distribution of FPRL1
in the human lung, an organ rich in vessels of different
types and a variety of other cell types, such as epithelial,
inflammatory, and immune cells. We observed FPRL1
not only in macrophages, neutrophils, and airway
epithelium, but also in endothelial cells (Figure 5c).
Sections stained with a control serum did not show any
positive staining (Figure 5d).
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Figure 4
Effects of LL-37 on endothelial cells in
vitro. (a) In vitro proliferation assays. Dif-
ferent concentrations of LL-37 and con-
trols were added to cultivated HUVECs.
Numbers at the left of the graph indicate
the numbers of cells per microliter of vol-
ume after 72 hours. VEGF was used as
positive control. Additionally, we tested
sLL-37, HNP-1, -2, and -3, hBD-3, and
the propeptides hCAP-18. In vitro prolif-
eration was not inhibited by human
serum. Application of the FPRL1 agonist
peptide WKYMVm (W peptide) results in
increased growth of cell numbers. Addi-
tion of antiserum to FPRL1 blunted
increased cellular proliferation induced by
LL-37. *P < 0.05 as compared with the con-
trol group (n = 10/group). (b and c) Ham-
ster aortic ring–sprouting assay. The addi-
tion of LL-37 to the culture medium resulted
in increased sprouting from the aortic rings
as compared with control groups that
received bFGF or no peptide (b). *P < 0.05
in the LL-37 and bFGF groups as compared
with the controls (n = 7/group) (c). aFPRL1,
antiserum plus FPRL1. 
Figure 5
Endothelial cells express FPRL1 in vitro and in vivo. (a) Detection of
FPRL1 transcripts in cultivated HUVECs by RT-PCR. Control is the
BEAS-2B cell line. (b) Detection of FPRL1 protein in HUVECs by West-
ern blot analysis using a specific antiserum. (c) Immunohistochem-
istry revealed expression in endothelial cells (arrow) of sections of lung
tissue. (d) Control serum revealed no positive staining. Bar: 60 µm.
To provide further evidence for a functional role of
FPRL1 in LL-37–induced endothelial activities, the
FPRL1-agonistic hexapeptide WKYMVm (31) was
applied to HUVECs and was found to stimulate pro-
liferation to an extent similar to LL-37 (Figure 4a). The
involvement of FPRL1 in endothelial stimulation by
LL-37 was supported by inhibition studies using per-
tussis toxin, an inhibitor of G protein–coupled recep-
tors that abolished effects of LL-37 on endothelial
cells, including proliferation (data not shown).
Intriguingly, a neutralizing antiserum to FPRL1 com-
pletely blocked the proliferative effect of LL-37 in
vitro, whereas a control serum had no effect (Figure
4a). These results show that FPRL1 is expressed on
endothelial cells and is necessary and sufficient to
mediate the angiogenic activity of LL-37.
Downstream events of FPRL1 activation involve
increased intracellular calcium (32) and diverse signal-
ing pathways, including the activation of the cytosolic
phospholipase A2, PI3K, and PLC (33). Using a calci-
um-imaging system we found that addition of LL-37 to
the medium of cultured endothelial cells at final con-
centrations from 2 to 10 µg/ml resulted in an increase
of intracellular Ca2+ (Figure 6a). The LL-37–specific
increase of intracellular Ca2+ could be cross-desensi-
tized by preincubation with N-formyl-methionyl-
leucyl-phenylalanine (fMLP-peptide), which also
induced a rise in intracellular calcium when solely
applied to the cells (Figure 6b). Also, preincubation
with pertussis toxin inhibited the rise in intracellular
Ca2+ after application of LL-37 (Figure 6a). In addition,
we could demonstrate that LL-37/hCAP-18 induced
nuclear translocation of NF-κB (Figure 6c). This reac-
tion was inhibited by the PKC-inhibitor (GF109203X)
and the addition of the antioxidant N-acetylcystein
(Figure 6c). Addition of GF109203X completely abol-
ished the LL-37–induced increase in proliferation (data
not shown). To investigate involvement of MAPK extra-
cellular signal-regulated kinase-1 and -2 (Erk-1 and -2)
and p38 MAPK, we used PD98059 and SB203580,
respectively. PD98059, but not SB203580, inhibited the
LL-37–mediated endothelial proliferation (data not
shown) indicating that Erk-1 and -2 may also be
involved in LL-37–elicited effects. Furthermore, we test-
ed the potential involvement of the PI3K/Akt-kinase
pathways by using the PI3K inhibitor wortmannin.
Although wortmannin only partially reduced NF-κB
translocation (Figure 6c), it strongly reduced LL-37–
induced endothelial cell growth (data not shown).
Additionally, we tested whether antiapoptotic effects of
LL-37 might contribute to the proliferative effect; how-
ever, we could not detect any effect in the annexin
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Figure 6
LL-37 binds to endothelial FPRL1 and induces cellular signaling. (a and b) LL-37 induces Ca2+ flux in HUVECs. Fura-2–loaded HUVECs were
stimulated with LL-37, and relative levels of intracellular Ca2+ were monitored using a calcium-imaging system. Local application of LL-37 led
to a concentration-dependent increase of intracellular calcium. Preincubation of the cells with pertussis toxin (Ptx) resulted in partial inhibi-
tion of the Ca2+ flux (a). Preincubation with fMLP cross-desensitized the LL-37–induced Ca2+ mobilization; sLL-37 had no effect (b). (c) LL-37
activates NF-κB in endothelial cells. This response can be inhibited by GF109203X and the addition of N-acetylcystein. *P < 0.05 as compared
with the control group (n = 8). NAC, N-acetylcystein.
V–binding assay (data not shown). Taken together, our
data suggest that LL-37 is able to stimulate several sig-
naling pathways involved in endothelial proliferation.
Discussion
The main finding of our study is the capability of the
human cathelicidin peptide LL-37 to induce function-
ally important angiogenesis. Several lines of evidence
suggest that LL-37–induced neovascularization is
mediated by a direct effect on endothelial cells involv-
ing the specific receptor FPRL1. Our ex vivo studies
using the aortic ring assay confirm that a direct activi-
ty of LL-37 on endothelial cells is involved in vivo.
Application of LL-37 in vivo resulted in vessel growth
in models of physiologic and pathologic angiogenesis.
In addition, we demonstrate that mice missing the
murine homologue of LL-37/hCAP-18 show decreased
wound vascularization.
The mechanism of angiogenic activity of LL-37 is
dependent on binding of the peptide to FPRL1, a G
protein–coupled receptor recently found to mediate
cellular responses to LL-37 (14). We demonstrate that
endothelial cells express functional FPLR1 and that
effects of LL-37 are specifically mediated by FPRL1.
Other cationic antimicrobial peptides and the propep-
tide hCAP-18 did not stimulate endothelial cells. In
contrast, the propeptide of the rabbit cathelicidin 
CAP-18 shows biological activity by blocking lipo-
polysaccharide-induced activation of leukocytes (34).
The angiogenic mechanism of LL-37 is clearly distinct
from the one described for PR-39, a porcine catheli-
cidin peptide, which appears to affect angiogenesis by
inhibiting the ubiquitin-proteasome–dependent degra-
dation of HIF-1α (35). The possibility of an indirect
effect of LL-37 by production of VEGF is unlikely
because addition of LL-37 to HUVECs did not lead to
release of VEGF in the supernatant and neutralizing
anti-VEGF did not reduce LL-37–induced endothelial
proliferation. Our analysis of signal transduction
pathways involved in LL-37–elicited endothelial acti-
vation revealed involvement of the PLC-γ/PKC/NF-κB,
the Erk-1 and -2 MAPK, and the PI3K/Akt pathways. As
well as its direct angiogenic effect on endothelial cells,
LL-37 may initiate vessel growth by attracting neu-
trophils and monocytes in vivo. These cells contain sig-
nificant amounts of angiogenic mediators that are
released in response to cellular activation (5, 36) and
are attracted by LL-37 (5, 14).
Our findings extend the spectrum of functions of
human antimicrobial peptides, demonstrating a direct
role in angiogenesis. LL-37/hCAP-18 expression is
increased during inflammation and in wound areas (5,
9, 11, 14, 22). Significant concentrations of LL-37 are
found in body fluids during inflammatory diseases (9,
37). In addition to its antimicrobial activities, LL-37/
hCAP functions in galvanizing innate and adaptive
immunity by activation of neutrophils, monocytes, and
lymphocyte subsets (14). Here we show that LL-37/
hCAP-18 is also able to induce angiogenesis, a process
essential for host defense, wound healing, and tissue
repair. In experimental, sterile wounds, keratinocytes
upregulate LL-37/hCAP-18 within 24 hours after the
incision (22). In addition to epithelial cells, the catheli-
cidin peptide is secreted from inflammatory cell types
such as neutrophils and macrophages that invade
wound areas. With several cellular sources, the peptide
likely reaches high local concentrations that are in the
range of antimicrobial, chemoattractant, and angio-
genic activity. The angiogenic effect of LL-37 is not
inhibited by the presence of human serum as described
for the peptide’s antimicrobial activity (30) and there-
fore is likely active in vivo.
In conclusion, the human endogenous peptide
antibiotic LL-37/hCAP-18 induces functionally impor-
tant angiogenesis. This angiogenic activity is mediated
by a direct effect on endothelial cells. Together with its
antimicrobial and immunomodulatory functions, 
LL-37/hCAP-18 links inflammation and host defense
with angiogenesis. The peptide, its analogues, and
other agonists of FPRL1 may prove to be effective
agents for induction of therapeutic angiogenesis. The
clinical relevance of such an approach is illustrated by
the observation that infection and impaired blood sup-
ply contribute to a variety of important human dis-
eases, including foot and leg ulcers associated with dia-
betes or burn wounds.
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